HORIZON-HLTH-2022-DISEASE-06-two-stage
HORIZON-HLTH-2022-DISEASE-06-two-stage
- Programme
- HORIZON
- Funded projects (dataset)
- 27
- EU contribution (sum)
- €178,205,342
- Portal deadline
- —
Leading topic in historical projects: HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- EUROPEAN VACCINE INITIATIVE3 coordinated
- INSERM3 coordinated
- RADBOUDUMC3 coordinated
- TBVI2 coordinated
- Leiden University Medical Center1 coordinated
- CECS1 coordinated
- FONDAZIONE TELETHON ETS1 coordinated
- FFIS DE LA REGION DE MURCIA1 coordinated
- University of Iceland1 coordinated
- INSTITUTE OF GENETIC DESEASES1 coordinated
- IRFMN1 coordinated
- KU Leuven1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- CNRS6 topic projects
- UOXF4 topic projects
- VACCINE FORMULATION INSTITUTE(CH)LTD4 topic projects
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS3 topic projects
- ERASMUS MC3 topic projects
- FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE3 topic projects
- KING'S COLLEGE LONDON3 topic projects
- OSR3 topic projects
- SSI3 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- UOXF · VACCINE FORMULATION INSTITUTE(CH)LTD3 shared
UK ↔ CH
- 3 shared
- 2 shared
- RADBOUDUMC · UKHD2 shared
NL ↔ DE
- 2 shared
- 2 shared
- NOVAVAX AB · UOXF2 shared
SE ↔ UK
- 2 shared
- 2 shared
- SSI · Leiden University Medical Center2 shared
DK ↔ NL
- 2 shared
- 2 shared
- MHRA · Leiden University Medical Center2 shared
UK ↔ NL
- TBVI · UNIVERSITE DE TOULOUSE2 shared
NL ↔ FR
- ILTOO PHARMA · INSERM2 shared
FR ↔ FR
- 2 shared
- ERASMUS MC · IST ID2 shared
NL ↔ PT
- 2 shared
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 11.7
- Median orgs / project
- 11
- Min / max orgs
- 4 – 21
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- France50
- Germany45
- Netherlands36
- United Kingdom32
- Spain31
- Italy17
- Belgium15
- Portugal11
- Austria11
- Switzerland10
- United States7
- Denmark5
- Sweden5
- Ireland5
- Greece4
- Finland4
- Czechia4
- Hungary4
Organization types
- university89 orgs · 118 rows
- research_institute49 orgs · 77 rows
- sme62 orgs · 64 rows
- other22 orgs · 27 rows
- company20 orgs · 25 rows
- public_body4 orgs · 5 rows
Topics in funded projects
- HORIZON-HLTH-2022-DISEASE-06-02-two-stageHORIZON-HLTH-2022-DISEASE-06-02-two-stage· 9 projects
- HORIZON-HLTH-2022-DISEASE-06-03-two-stageHORIZON-HLTH-2022-DISEASE-06-03-two-stage· 9 projects
- HORIZON-HLTH-2022-DISEASE-06-04-two-stageHORIZON-HLTH-2022-DISEASE-06-04-two-stage· 9 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| BAXERNA 2.0 Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines | HORIZON | €9,458,801 |
| SIMPATHIC Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology | HORIZON | €8,826,970 |
| CAPTIVATE CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies | HORIZON | €8,725,948 |
| Vax2Muc NEXT GENERATION VACCINES AGAINST GASTROINTESTINAL MUCOSAL PATHOGENS, USING HELICOBACTER PYLORI AS MODEL PATHOGEN | HORIZON | €8,219,843 |
| LightCure LightCure - Light for double specificity and efficacy without burden | HORIZON | €8,182,057 |
| EURAS EUropean network for neurodevelopmental RASopathies | HORIZON | €8,048,715 |
| RESTORE VISION Novel advanced and repurposed therapeutics for vision restoration in a group of severe rare ocular surface diseases: from validation to first clinical investigations | HORIZON | €7,999,852 |
| GEREMY Gene Therapy for treatment of rare inherited Arrhythmogenic Cardiomyopathy | HORIZON | €7,774,104 |
| FLUniversal Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses | HORIZON | €7,567,788 |
| WORMVACS2.0 Innovations for vaccines against helminth infections | HORIZON | €7,475,302 |
| TheRaCil Therapies for Renal Ciliopathies | HORIZON | €7,425,447 |
| NOSEVAC INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TRACT | HORIZON | €7,369,449 |
| ARTiDe Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe) | HORIZON | €6,998,038 |
| DREAMS Drug REpurposing with Artificial intelligence for Muscular disorderS | HORIZON | €6,952,110 |
| MAGIC Next-generation models and genetic therapies for rare neuromuscular diseases | HORIZON | €6,553,472 |